Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

Eli Lilly and Company taps Durham for 450+ jobs, new facility

Eli Lilly and Company plans to bring more than 462 jobs to a new Durham County facility. The drug giant picked Durham County for a $474 million investment over competing sites in both Indiana and Pennsylvania.…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/dna-strand-assembling-from-different-elements-STB4YJR-1-1.jpg

Sarepta plans gene editing center; files DMD therapy for review

Genetic disease-focused firms need infrastructure says Sarepta, which shared plans for a gene editing center of excellence at the JP Morgan healthcare conference. The gene editing center will be in Durham, North Carolina according to…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/phasebio.png

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agreement with Viamet Pharmaceuticals Holdings, LLC and…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/precision_revised_logo_1_color.png

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy

Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted its…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/phasebio.png

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/invented-at-duke.2019.0028-1.jpg

SeaSpine® Announces Exclusive Development and Licensing Agreement with restor3D®

September 24, 2019 CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/Four-Points-logo-01-1.png

Duke University & Deerfield Management Announce Four Points Innovation

 Deerfield Commits up to $130 million to Accelerate Drug Discovery at Duke Through a Newly Launched Company Visit Four Points Innovation (Durham, NC and New York, NY, December 18, 2019)—Duke University and Deerfield Management Company, a healthcare investment firm, today announced the creation of…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/bandage-1.jpg

Bandage heals broken bones by trapping a biochemical

When a bone-break occurs, the body floods the injury site with a healing biochemical known as adenosine. A new bandage is designed to absorb that substance, keeping it around so it can do more work.…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/precision_revised_logo_1_color.png

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting

Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced updated interim clinical data from the ongoing Phase 1 trial of its…

Read More